Do analysts rate CARM or EVGN?

Carisma Therapeutics presently has a consensus target price of $1.00, indicating a potential upside of 39,900.00%. Given Carisma Therapeutics' higher possible upside, equities research analysts plainly believe Carisma Therapeutics is more favorable than Evogene. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Do analysts prefer CARM or IMCC?

Carisma Therapeutics presently has a consensus price target of $1.00, indicating a potential upside of 39,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Carisma Therapeutics is more favorable than IM Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer HEPA or CARM?

Carisma Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 39,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Carisma Therapeutics is more favorable than Hepion Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer CARM or JAGX?

Carisma Therapeutics presently has a consensus price target of $1.00, suggesting a potential upside of 39,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Carisma Therapeutics is more favorable than Jaguar Animal Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Jaguar Animal Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CARM or JAGX more profitable?

Jaguar Animal Health has a net margin of -169.04% compared to Carisma Therapeutics' net margin of -254.28%. Company Net Margins Return on Equity Return on Assets Carisma Therapeutics -254.28% N/A -192.17% Jaguar Animal Health -169.04% N/A -115.55%

Do analysts prefer BPTSY or CARM?

Carisma Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 39,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Carisma Therapeutics is more favorable than Biophytis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biophytis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, BPTSY or CARM?

Biophytis has higher earnings, but lower revenue than Carisma Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biophytis N/A N/A -$18.43M N/A N/A Carisma Therapeutics $10.77M 0.01 -$60.48M $0.73 0.00

Is BPTSY or CARM more profitable?

Biophytis has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Company Net Margins Return on Equity Return on Assets Biophytis N/A N/A N/A Carisma Therapeutics -254.28% N/A -192.17%

Carisma Therapeutics (CARM) Competitors

$0.0025 0.00 (0.00%)

As of 08/6/2026 12:07 PM Eastern

Compare

CARM vs. EVGN, IMCC, HEPA, JAGX, and BPTSY

Should you buy Carisma Therapeutics stock or one of its competitors? MarketBeat compares Carisma Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Carisma Therapeutics include Evogene (EVGN), IM Cannabis (IMCC), Hepion Pharmaceuticals (HEPA), Jaguar Animal Health (JAGX), and Biophytis (BPTSY).

How does Carisma Therapeutics compare to Evogene?

Carisma Therapeutics (NASDAQ:CARM) and Evogene (NASDAQ:EVGN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by insiders. Comparatively, 7.4% of Evogene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Carisma Therapeutics has a net margin of -254.28% compared to Evogene's net margin of -638.12%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Evogene	-638.12%	-158.82%	-80.37%

Carisma Therapeutics presently has a consensus target price of $1.00, indicating a potential upside of 39,900.00%. Given Carisma Therapeutics' higher possible upside, equities research analysts plainly believe Carisma Therapeutics is more favorable than Evogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Evogene had 1 more articles in the media than Carisma Therapeutics. MarketBeat recorded 1 mentions for Evogene and 0 mentions for Carisma Therapeutics. Carisma Therapeutics' average media sentiment score of 0.00 equaled Evogene'saverage media sentiment score.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Evogene	Neutral

Carisma Therapeutics has a beta of -9.09, meaning that its stock price is 1,009% less volatile than the broader market. Comparatively, Evogene has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

Evogene has lower revenue, but higher earnings than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.01	-$60.48M	$0.73	0.00
Evogene	$1.84M	3.24	-$8.48M	-$1.39	N/A

Summary

Carisma Therapeutics and Evogene tied by winning 8 of the 16 factors compared between the two stocks.

How does Carisma Therapeutics compare to IM Cannabis?

Carisma Therapeutics (NASDAQ:CARM) and IM Cannabis (NASDAQ:IMCC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Carisma Therapeutics has a beta of -9.09, suggesting that its stock price is 1,009% less volatile than the broader market. Comparatively, IM Cannabis has a beta of 2.07, suggesting that its stock price is 107% more volatile than the broader market.

44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 7.7% of IM Cannabis shares are held by institutional investors. 6.9% of Carisma Therapeutics shares are held by company insiders. Comparatively, 5.9% of IM Cannabis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

IM Cannabis has higher revenue and earnings than Carisma Therapeutics. IM Cannabis is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.01	-$60.48M	$0.73	0.00
IM Cannabis	$39.17M	0.02	-$8.10M	-$1.75	N/A

IM Cannabis has a net margin of -27.65% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat IM Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
IM Cannabis	-27.65%	-585.96%	-39.96%

Carisma Therapeutics presently has a consensus price target of $1.00, indicating a potential upside of 39,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Carisma Therapeutics is more favorable than IM Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Carisma Therapeutics' average media sentiment score of 0.00 equaled IM Cannabis'average media sentiment score.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
IM Cannabis	Neutral

Summary

Carisma Therapeutics beats IM Cannabis on 8 of the 14 factors compared between the two stocks.

How does Carisma Therapeutics compare to Hepion Pharmaceuticals?

Hepion Pharmaceuticals (NASDAQ:HEPA) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Hepion Pharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%
Carisma Therapeutics	-254.28%	N/A	-192.17%

In the previous week, Hepion Pharmaceuticals had 1 more articles in the media than Carisma Therapeutics. MarketBeat recorded 1 mentions for Hepion Pharmaceuticals and 0 mentions for Carisma Therapeutics. Hepion Pharmaceuticals' average media sentiment score of 0.67 beat Carisma Therapeutics' score of 0.00 indicating that Hepion Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Hepion Pharmaceuticals	Positive
Carisma Therapeutics	Neutral

Carisma Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 39,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Carisma Therapeutics is more favorable than Hepion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

17.2% of Hepion Pharmaceuticals shares are held by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are held by institutional investors. 0.1% of Hepion Pharmaceuticals shares are held by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Hepion Pharmaceuticals has higher earnings, but lower revenue than Carisma Therapeutics. Hepion Pharmaceuticals is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A
Carisma Therapeutics	$10.77M	0.01	-$60.48M	$0.73	0.00

Hepion Pharmaceuticals has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of -9.09, indicating that its stock price is 1,009% less volatile than the broader market.

Summary

Carisma Therapeutics beats Hepion Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Carisma Therapeutics compare to Jaguar Animal Health?

Carisma Therapeutics (NASDAQ:CARM) and Jaguar Animal Health (NASDAQ:JAGX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Carisma Therapeutics has a beta of -9.09, indicating that its share price is 1,009% less volatile than the broader market. Comparatively, Jaguar Animal Health has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market.

In the previous week, Jaguar Animal Health had 2 more articles in the media than Carisma Therapeutics. MarketBeat recorded 2 mentions for Jaguar Animal Health and 0 mentions for Carisma Therapeutics. Carisma Therapeutics' average media sentiment score of 0.00 equaled Jaguar Animal Health'saverage media sentiment score.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Jaguar Animal Health	Neutral

Jaguar Animal Health has a net margin of -169.04% compared to Carisma Therapeutics' net margin of -254.28%.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Jaguar Animal Health	-169.04%	N/A	-115.55%

Jaguar Animal Health has higher revenue and earnings than Carisma Therapeutics. Jaguar Animal Health is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.01	-$60.48M	$0.73	0.00
Jaguar Animal Health	$11.51M	0.05	-$53.43M	-$591.92	N/A

Carisma Therapeutics presently has a consensus price target of $1.00, suggesting a potential upside of 39,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Carisma Therapeutics is more favorable than Jaguar Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Jaguar Animal Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 12.0% of Jaguar Animal Health shares are held by institutional investors. 6.9% of Carisma Therapeutics shares are held by company insiders. Comparatively, 2.0% of Jaguar Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Carisma Therapeutics and Jaguar Animal Health tied by winning 7 of the 14 factors compared between the two stocks.

How does Carisma Therapeutics compare to Biophytis?

Biophytis (NASDAQ:BPTSY) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

0.1% of Biophytis shares are held by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are held by institutional investors. 3.7% of Biophytis shares are held by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Biophytis' average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company	Overall Sentiment
Biophytis	Neutral
Carisma Therapeutics	Neutral

Carisma Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 39,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Carisma Therapeutics is more favorable than Biophytis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biophytis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Biophytis has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company	Net Margins	Return on Equity	Return on Assets
Biophytis	N/A	N/A	N/A
Carisma Therapeutics	-254.28%	N/A	-192.17%

Biophytis has a beta of 2.46, suggesting that its stock price is 146% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of -9.09, suggesting that its stock price is 1,009% less volatile than the broader market.

Biophytis has higher earnings, but lower revenue than Carisma Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biophytis	N/A	N/A	-$18.43M	N/A	N/A
Carisma Therapeutics	$10.77M	0.01	-$60.48M	$0.73	0.00

Summary

Carisma Therapeutics beats Biophytis on 6 of the 10 factors compared between the two stocks.

Get Carisma Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CARM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CARM vs. The Competition

Export

Metric	Carisma Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$105K	$11.73B	$6.95B	$12.87B
Dividend Yield	N/A	2.71%	2.59%	9.93%
P/E Ratio	0.00	791.86	271.11	25.30
Price / Sales	0.01	744.66	600.09	82.38
Price / Cash	N/A	72.59	71.89	50.37
Price / Book	0.00	10.81	13.05	6.13
Net Income	-$60.48M	$2.79B	$3.46B	$342.95M
7 Day Performance	N/A	3.24%	3.43%	3.19%
1 Month Performance	N/A	-1.69%	-2.65%	-1.98%
1 Year Performance	N/A	193.27%	76.02%	21.11%

Carisma Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CARM Carisma Therapeutics	1.919 of 5 stars	$0.00 flat	$1.00 +39,900.0%	-99.2%	$105K	$10.77M	0.00	20
EVGN Evogene	0.6492 of 5 stars	$0.49 -4.9%	N/A	-45.2%	$4.53M	$3.85M	N/A	140	Gap Up
IMCC IM Cannabis	0.3617 of 5 stars	$0.11 +1.3%	N/A	-95.1%	$670K	$39.17M	N/A	340	Gap Down
HEPA Hepion Pharmaceuticals	N/A	$0.06 -10.3%	N/A	+49.3%	$669K	N/A	N/A	20	Gap Down
JAGX Jaguar Animal Health	0.3878 of 5 stars	$0.96 -3.6%	N/A	-98.8%	$600K	$11.51M	N/A	50	News Coverage Upcoming Earnings Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CARM) was last updated on 8/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Carisma Therapeutics (CARM) Competitors

CARM vs. EVGN, IMCC, HEPA, JAGX, and BPTSY

How does Carisma Therapeutics compare to Evogene?

Summary

How does Carisma Therapeutics compare to IM Cannabis?

Summary

How does Carisma Therapeutics compare to Hepion Pharmaceuticals?

Summary

How does Carisma Therapeutics compare to Jaguar Animal Health?

Summary

How does Carisma Therapeutics compare to Biophytis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARM vs. The Competition

Carisma Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Carisma Therapeutics (CARM) Competitors

CARM vs. EVGN, IMCC, HEPA, JAGX, and BPTSY

How does Carisma Therapeutics compare to Evogene?

Do insiders & institutionals believe in CARM or EVGN?

Is CARM or EVGN more profitable?

Do analysts rate CARM or EVGN?

Does the media refer more to CARM or EVGN?

Which has more volatility and risk, CARM or EVGN?

Which has stronger earnings & valuation, CARM or EVGN?

Summary

How does Carisma Therapeutics compare to IM Cannabis?

Which has more risk and volatility, CARM or IMCC?

Do institutionals and insiders have more ownership in CARM or IMCC?

Which has higher valuation and earnings, CARM or IMCC?

Is CARM or IMCC more profitable?

Do analysts prefer CARM or IMCC?

Does the media prefer CARM or IMCC?

Summary

How does Carisma Therapeutics compare to Hepion Pharmaceuticals?

Is HEPA or CARM more profitable?

Does the media refer more to HEPA or CARM?

Do analysts prefer HEPA or CARM?

Do insiders & institutionals hold more shares of HEPA or CARM?

Which has higher earnings and valuation, HEPA or CARM?

Which has more risk & volatility, HEPA or CARM?

Summary

How does Carisma Therapeutics compare to Jaguar Animal Health?

Which has more volatility and risk, CARM or JAGX?

Does the media refer more to CARM or JAGX?

Is CARM or JAGX more profitable?

Which has stronger valuation & earnings, CARM or JAGX?

Do analysts prefer CARM or JAGX?

Do institutionals & insiders hold more shares of CARM or JAGX?

Summary

How does Carisma Therapeutics compare to Biophytis?

Do insiders & institutionals hold more shares of BPTSY or CARM?

Does the media favor BPTSY or CARM?

Do analysts prefer BPTSY or CARM?

Is BPTSY or CARM more profitable?

Which has more volatility & risk, BPTSY or CARM?

Which has stronger earnings and valuation, BPTSY or CARM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARM vs. The Competition

Carisma Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools